European Undervalued Small Caps With Insider Action August 2026
In recent weeks, European markets have experienced a notable uptick, with the STOXX Europe 600 Index climbing by 1.70% amid resilient earnings and improved risk appetite despite ongoing geopolitical uncertainties. As investors navigate this landscape, small-cap stocks in Europe present intriguing opportunities for those seeking to capitalize on potential undervaluation and insider activity, which can be indicative of confidence in a company's prospects.
Top 10 Undervalued Small Caps With Insider Buying In Europe
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Eurocell | 12.2x | 0.3x | 46.66% | ★★★★★☆ |
| Nederman Holding | 19.0x | 0.8x | 24.73% | ★★★★★☆ |
| Bilia | 16.0x | 0.3x | 31.54% | ★★★★☆☆ |
| NoHo Partners Oyj | 15.9x | 0.4x | 31.66% | ★★★★☆☆ |
| Franchise Brands | 26.9x | 2.0x | 48.09% | ★★★★☆☆ |
| Linc | 13.1x | 13.6x | 29.86% | ★★★★☆☆ |
| CellaVision | 28.2x | 4.9x | 41.87% | ★★★☆☆☆ |
| Travis Perkins | NA | 0.3x | -80.06% | ★★★☆☆☆ |
| Samhällsbyggnadsbolaget i Norden | NA | 3.3x | -126.45% | ★★★☆☆☆ |
| John Mattson Fastighetsföretagen | 8.1x | 6.3x | 1.41% | ★★★☆☆☆ |
Here's a peek at a few of the choices from the screener.
Afentra (AIM:AET)
Simply Wall St Value Rating: ★★★★☆☆
Overview: Afentra is focused on the exploration and production of oil and gas, with a market capitalization of approximately £32.57 million.
Operations: Afentra's revenue is primarily derived from its Oil & Gas - Exploration & Production segment, with a reported revenue of $114.39 million for the latest period. The company experienced fluctuations in its gross profit margin, reaching 50.69% at one point before dropping to 38.12%. Operating expenses have varied over time, impacting net income margins significantly across different periods.
PE: -82.3x
Afentra, a small European energy player, recently completed a £2 million equity offering at £0.67 per share, enhancing its financial flexibility. Despite past shareholder dilution and reliance on external borrowing, insider confidence is evident with Anastasia Deulina's purchase of 129,522 shares valued at approximately £78K. The company secured a 35% interest in Angola's Block KON4 and anticipates future growth with earnings projected to rise by over 50% annually. However, the recent resignation of CFO Deulina may introduce transitional challenges as they remain until February 2027 for an orderly handover.
- Take a closer look at Afentra's potential here in our valuation report.
Assess Afentra's past performance with our detailed historical performance reports.
Card Factory (LSE:CARD)
Simply Wall St Value Rating: ★★★★★☆
Overview: Card Factory is a retailer specializing in greeting cards, gifts, and celebration essentials with operations primarily through its physical stores, complemented by digital sales and wholesale partnerships, boasting a market cap of approximately £0.76 billion.
Operations: Cardfactory generates revenue primarily from its stores (£514.60 million), digital channels (£20.60 million), and wholesale partnerships (£47.20 million). Over recent periods, the company has experienced fluctuations in its net income margin, with a notable trend of decreasing margins from 0.1674% in 2015 to 0.0535% by early 2026, indicating increased costs or other financial pressures impacting profitability despite rising revenues.
PE: 8.1x
Card Factory, a European small-cap company, is attracting attention for its potential value. Despite a dip in profit margins from 8.8% to 5.4% over the past year, earnings are projected to grow at an annual rate of 11.52%. Insider confidence is evident through recent share purchases over the last quarter, signaling belief in future prospects. However, all liabilities are funded through external borrowing, adding risk to their financial structure.
- Get an in-depth perspective on Card Factory's performance by reading our valuation report here.
Review our historical performance report to gain insights into Card Factory's's past performance.
CellaVision (OM:CEVI)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: CellaVision specializes in developing and selling automated microscopy systems and reagents for hematology, with a market capitalization of SEK 8.23 billion.
Operations: The company's revenue is primarily derived from its Automated Microscopy Systems and Reagents in the field of hematology, with recent figures indicating a revenue of SEK 739.15 million. The gross profit margin has shown fluctuations over time, reaching 68.71% in the latest period. Operating expenses are significant, with notable allocations to sales and marketing as well as research and development efforts.
PE: 28.2x
CellaVision, a player in the biotechnology sector, recently appointed Steve Ferguson as CEO, bringing over 25 years of industry experience. Despite facing a dip in net income for Q2 2026 to SEK 32.63 million from SEK 37.61 million last year, insider confidence is evident with Founder & Director Christer Fahraeus purchasing shares worth approximately SEK 31.51 million. Earnings are projected to grow annually by nearly 18%, although reliance on external borrowing poses some risk.
- Click to explore a detailed breakdown of our findings in CellaVision's valuation report.
Understand CellaVision's track record by examining our Past report.
Make It Happen
- Get an in-depth perspective on all 54 Undervalued European Small Caps With Insider Buying by using our screener here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com